Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for acute ischemic non-large-vessel occlusion stroke 4.5 to 9 hours after onset
ChiCTR2300067439Phase 4Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Mianyang Central Hospital. Primary endpoints: Proportion of subjects with modified Rankin Scale 0 to 1 at 90 days, Incidence of symptomatic intracranial hemorrhage and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300067439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067439.